MedTrace Logo

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

NCT00723359 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-07-18

No results posted yet for this study

Summary

This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.

Conditions

Interventions

DRUG

BT062

biologic

Sponsors & Collaborators

  • Biotest

    collaborator INDUSTRY

  • Biotest Pharmaceuticals Corporation

    lead INDUSTRY

Principal Investigators

  • Kenneth C. Anderson, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00723359 on ClinicalTrials.gov